RT Journal Article
SR Electronic
T1 Factors associated with onchocerciasis transmission after 20 years of community treatment with ivermectin in savanah and forest areas in Central African Republic : A Cross Sectional Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.02.24309819
DO 10.1101/2024.07.02.24309819
A1 Woromogo, Sylvain Honoré
A1 Garoua-Adjou, Stéphanie Inesse
A1 Ngouyombo, Ange Donatien Ben
A1 Doyama-Woza, Rodrigue Herman
A1 Diemer, Henri Saint Calvaire
A1 Longo, Jean de Dieu
YR 2024
UL http://medrxiv.org/content/early/2024/07/05/2024.07.02.24309819.abstract
AB The Central African Republic has endemic onchocerciasis in 20 health districts in savannah and forest areas. The country organised a mass distribution campaign of invermectin in 2023 through the National Onchocerciasis Control Programme. The objectives of this study were to identify factors of persistent transmission of onchocerciasis. A cross-sectional study was carried out in Bossangoa (savannah area) and Kémo (forest area) health districts. Using kelsey’formula 1600 respondents were recruited. Dependent variable is onchocerciasis status. Bivariate analysis was carried out to determine the differential risks for onchocerciasis infection, each variable being taken separately. The strength of statistical associations was measured by prevalence rates (PR) from log-binomial regression model and their 95% confidence intervals. Onchocerciasis prevalence is 26.45% in Bossangoa (95% CI = 23.76 - 29.14), and 14.79% (84/568) in Kémo (95% CI = 23.53 - 29.37). In both savannah and forest areas, the common factors incriminated in the transmission of onchocerciasis after several years of community distribution of ivermectin are: young age (PR = 2.44 (1.97 – 3.03), p < 0.001 ; 3.63 (2.32 – 5.70), p < 0.001 respectively), not taking ivermectin (PR = 2.31 (1.86 – 2.87), p < 0.001 ; 6.84 (4.42 – 10.57), p < 0.001 respectively), male sex (PR = 2.54 (2.04 – 3.16), p <0.001 ; 1.79 (1.19 – 2.69), p = 0.002 respectively), living near rivers and in rural areas. Despite efforts, the prevalence of onchocerciasis remains high in the 2 districts. The main factors incriminated in the persistence of transmission are failure to take ivermectin, male sex and young age. The National Onchocerciasis Control Programme needs to review its planning of activities, ensuring that the population is constantly made aware before drugs are distributed, and increasing the number of days of community-based distribution in order to improve therapeutic coverage.Synopsis Onchocerciasis is a disease called River Blindness and transmitted by the bites of infected blackflies that reproduction is in high-flow streams. This disease affects the skin (itching and nodules) and eyes (redness and even blindness). An effective treatment is ivermectin. Human activities near rivers contribute to the disease. Also, good coverage of ivermectin intake by the population considerably reduces the number of people affected. The question we asked ourselves was: why, after more than 20 years of community-based distribution of ivermectin in the Central African Republic, is onchocerciasis still being transmitted? The Central African Republic has made considerable efforts to combat onchocerciasis despite the war, but the number of people infected remains high. The study showed that in both the savannah and the forest, men are particularly at risk, not only because of their activities near rivers, but also because they do not protect their bodies as women do. We found a higher number of people affected in rural areas than in urban areas. In the community that adheres to ivermectin use, the number of people affected decreases. We recommended that the national onchocerciasis control programme take into account the habits of the population in order to plan and monitor their control activities (for example: increase the number of days ivermectin is distributed, and the number of days community awareness is raised).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Faculty of Health Sciences of the University of Bangui, Central African RepublicI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript